Influence of Copper Depletion on Iron Uptake Mediated by SFT, a Stimulator of Fe Transport*

Jianming Yu and Marianne Wessling-ResnickDagger

From the Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts 02115

    ABSTRACT
Top
Abstract
Introduction
Procedures
Results
Discussion
References

We recently identified a novel factor involved in cellular iron assimilation called SFT or Stimulator of Fe Transport (Gutierrez, J. A., Yu, J., Rivera, S., and Wessling-Resnick, M. (1997) J. Cell Biol. 149, 895-905). When stably expressed in HeLa cells, SFT was found to stimulate the uptake of both transferrin- and nontransferrin-bound Fe (iron). Assimilation of nontransferrin-bound Fe by HeLa cells stably expressing SFT was time- and temperature-dependent; both the rate and extent of uptake was enhanced relative to the activity of control nontransfected cells. Although the apparent Km for Fe uptake was unaffected by expression of SFT (5.6 versus 5.1 µM measured for control), the Vmax of transport was increased from 7.0 to 14.7 pmol/min/mg protein. Transport mediated by SFT was inhibitable by diethylenetriaminepentaacetic acid and ferrozine, Fe3+- and Fe2+-specific chelators. Because cellular copper status is known to influence Fe assimilation, we investigated the effects of Cu (copper) depletion on SFT function. After 4 days of culture in Cu-deficient media, HeLa cell Cu,Zn superoxide dismutase activity was reduced by more than 60%. Both control cells and cells stably expressing SFT displayed reduced Fe uptake as well; levels of transferrin-mediated import fell by ~80%, whereas levels of nontransferrin-bound Fe uptake were ~50% that of Cu-replete cells. The failure of SFT expression to stimulate Fe uptake above basal levels in Cu-depleted cells suggests a critical role for Cu in SFT function. A current model for both transferrin- and nontransferrin-bound Fe uptake involves the function of a ferrireductase that acts to reduce Fe3+ to Fe2+, with subsequent transport of the divalent cation across the membrane bilayer. SFT expression did not enhance levels of HeLa cell surface reductase activity; however, Cu depletion was found to reduce endogenous activity by 60%, suggesting impaired ferrireductase function may account for the influence of Cu depletion on SFT-mediated Fe uptake. To test this hypothesis, the ability of SFT to directly mediate Fe2+ import was examined. Although expression of SFT enhanced Fe2+ uptake by HeLa cells, Cu depletion did not significantly reduce this activity. Thus, we conclude that a ferrireductase activity is required for SFT function in Fe3+ transport and that Cu depletion reduces cellular iron assimilation by affecting this activity.

    INTRODUCTION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Mammalian cells can acquire iron either via the binding of Fe2-transferrin (Tf)1 to high affinity surface receptors and its subsequent internalization into endosomal compartments or through Tf-independent pathways utilizing plasma membrane-based transport systems (1, 2). Several lines of evidence suggest that Tf-dependent and -independent import involves at least two functional activities as follows: a ferrireductase that converts Fe3+ to Fe2+ and a carrier mechanism that subsequently translocates Fe2+ across membrane bilayers (3-8). Genetic studies in yeast have begun to identify a number of factors involved in membrane transport of Fe, and at least two uptake systems have been characterized: a high affinity transport mechanism involving FTR1 and FET3 (9, 10) and a low affinity activity provided by FET4 (11, 12). In addition, two ferrireductases, FRE1 and FRE2, are known to play a role in yeast iron transport (13, 14). Whereas FET4 can mediate the import of Fe2+ in the absence of ferrireductase activity (11), FTR1 is believed to be a transporter for iron that has been first reduced by FRE1 (or FRE2) and then oxidized by the multi-copper oxidase FET3 (2, 10). However, although it is presumed that FET3-oxidized Fe3+ is then translocated across the yeast membrane, the exact valency of transported iron and the precise function of FTR1 remain poorly defined. Nonetheless, an interesting connection between Cu and Fe metabolism has been revealed by the observation that FTR1 biosynthesis is impaired in the absence of Cu-requiring FET3 (10). The relationship between Cu and Fe transport in yeast (2) is highly reminiscent of the role of copper for iron metabolism in mammals (15). Dietary Cu deficiency leads to microcytic hypochromic anemia (16-18); this apparent iron deficiency appears to be promoted by the loss of oxidase activity provided by circulating ceruloplasmin, a Cu-requiring enzyme (19).

Although progress in characterizing the proteins involved in yeast Fe transport has been made, relatively little is known about mammalian uptake systems. Recently, two factors were identified to be involved in this process. DCT1 (or nRAMP2) was defined to function in rat intestinal iron uptake by the functional expression cloning of Fe2+ transport activity in Xenopus oocytes (20). Moreover, the mk mouse, which suffers from microcytic anemia due to inefficient iron absorption (21), was found to have a defect in the nRAMP2 gene; this missense mutation is predicted to impair nRAMP2 transport function (22). DCT1/nRAMP2 appears not only to mediate uptake of Fe2+, but it is capable of facilitating the translocation of other divalent cations as well (20). In contrast, a second transport protein that we have identified, called SFT or Stimulator of Fe Transport, enables Xenopus oocytes to take up iron presented as Fe3+, and this activity is inhibited by Cd2+ but not other divalent cations (23). Our preliminary investigation of SFT function in mammalian cells revealed its capacity to also stimulate the assimilation of Fe from the Tf-mediated pathway. Here, we report a more detailed functional characterization of the stimulation of SFT of non-Tf-bound Fe uptake in mammalian cells. These studies define the function of SFT in promoting the uptake of iron presented to cells as either Fe2+ or Fe3+. Furthermore, we explored the potential role of copper for the activity of SFT by depleting cells in culture with Cu-deficient media (24). Our results demonstrate that Cu depletion decreases both Tf- and non-Tf-bound Fe uptake by HeLa cells and that the function of SFT is impaired under these conditions. Cu depletion was also found to partially inhibit a cell surface ferrireductase, implicating a role for this activity in SFT-mediated import of Fe3+. This idea is strongly supported by the finding that SFT-stimulated Fe2+ uptake is unaffected in Cu-depleted cells.

    EXPERIMENTAL PROCEDURES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Cell Culture and Preparation for Experiments-- HeLa cells stably expressing a green fluorescent protein (GFP) chimera of SFT, referred to here as HeLa(SFT), were previously established (23). HeLa(SFT) and HeLa cells were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 300 g/liter L-glutamine, 10% fetal bovine serum, 50 units/ml penicillin G, and 50 µg/ml streptomycin. For some experiments, cells were cultured under the same conditions, except that serum was Cu-depleted as described below. For transport assays, cells were grown to near confluence in 6-well (35-mm) plates. In preparation for ferrireductase assays, HeLa cells were washed three times with ice-cold phosphate-buffered saline (PBS), followed by one additional wash in Hanks' buffer (137 mM NaCl, 5.36 mM KCl, 1.3 mM CaCl2, 410 µM MgSO4, 490 µM MgCl2, 337 µM Na2HPO4, 440 µM KH2PO4, 4.17 mM NaHCO3, and 5.55 mM dextrose).

Iron Uptake Measurements-- 55FeCl3 was purchased from NEN Life Science Products (>3 mCi/mg). 55Fe-nitrilotriacetic acid (NTA) was prepared by complexing 55Fe with a 4-fold molar excess of NTA in 20 mM HEPES-Tris, pH 6.0, 100 mM NaCl; this mixture was then adjusted to pH 7 with NaOH essentially as described by Teichmann and Stremmel (25). To start uptake assays, HeLa cells were incubated in serum-free DMEM for 1 h, and then fresh serum-free DMEM was added with specified concentrations of 55FeNTA. Transport assays were performed at 37 or 4 °C for times indicated in the figure legends. To quench uptake, cells were rapidly placed on ice, washed three times with ice-cold PBS, and then incubated on ice with 1000-fold molar excess unlabeled FeNTA for 20 min to remove nonspecifically bound iron (26). Six hundred µl of PBS containing 1 mM EDTA were added to each well to lift cells, and the amount of cell-associated radioactivity was measured by scintillation counting of duplicate 200-µl aliquots of this cell suspension. A 40-µl aliquot of the cell suspension was solubilized with Triton X-100 (0.1% final concentration), and protein content was determined by the Bradford assay using bovine serum albumin as a standard (27). Uptake was calculated as femtomoles of 55Fe per µg of cell protein. For some experiments, cells were incubated at 37 or 4 °C with 55Fe3+ in the presence of freshly dissolved ascorbate at a 1:20 molar ratio (final concentrations were 1 µM 55FeCl3 and 20 µM ascorbate). Accumulation of 55Fe from Tf was measured as previously detailed (23). HeLa cells were incubated with 40 nM [55Fe]Tf at 37 °C for 3 h and then washed in ice-cold PBS, followed by a 45-min incubation on ice with 1 µM unlabeled Tf to remove surface-bound radioactivity. After three additional washes with ice-cold PBS, cells from each well were harvested in 600 µl of PBS containing 1 mM EDTA. The amount of radioactivity in duplicate 200-µl aliquots was measured, and the protein concentration was determined as described above.

Serum Cu Depletion and Superoxide Dismutase (SOD) Activity Measurements-- Cu depletion of serum was carried out as described by Tong et al. (24). Briefly, serum was dialyzed at 4 °C against two changes (12 h each) of 30 mM TriethylenetetramineTM (TRIEN) in PBS. To eliminate TRIEN, the serum was further dialyzed against three changes of PBS. The serum protein concentration was found to be the same before and after dialysis. To replete the dialyzed serum, CuCl2 was added at a final concentration of 2 µM.

To determine the Cu status of HeLa cells, Cu,Zn-SOD activity was measured following the protocol of Percival (28). Cells were washed three times in ice-cold PBS and then suspended in 0.5 mM EDTA, pH 8, containing 0.1 mM phenylmethylsulfonyl fluoride and 0.5 mg/liter pepstatin A (108 cells/ml). After being frozen and thawed twice to ensure disruption of cell membranes, a cytosolic fraction was collected upon centrifugation at 100,000 × g for 45 min at 4 °C. SOD assays were performed by incubating 50-µl aliquots of the cytosol with 250 µl of pyrogallol reagent (1 mM pyrogallol in 10 mM HCl and 1 mM diethylenetriaminepentaacetic acid) and 500 µl of 50 mM Tris-HCl, pH 8.2. After a 3-min incubation at room temperature, the reaction products were measured spectrophotometrically at 340 nm. The activity of Cu,Zn-SOD was determined by subtracting the activity due to the mangano form of SOD found in cytosol treated with 2.0 mM KCN. Enzyme activity was expressed as Delta A340/106 cells.

Ferrireductase Assays-- Extracellular ferrireductase activity was monitored by the cell-mediated production of membrane-impermeant ferrocyanide from ferricyanide (5, 29). In brief, HeLa cells were washed in ice-cold PBS three times, followed by a final wash with Hanks' buffer and then incubated in Hanks' buffer with K3Fe(CN)6 at 37 or 4 °C. To stop ferricyanide reduction, the cells were rapidly chilled on ice; to measure the amount of ferrocyanide produced, a 700-µl aliquot of the cell-conditioned media was mixed with, in order, 100 µl of 3 M sodium acetate, pH 6.4, 100 µl of 0.2 M citric acid, 50 µl of 3.34 mg/ml bathophenanthroline sulfonate, and 50 µl of 3.3 mM FeCl3 prepared in 0.1 M acetic acid. After this reaction was allowed to proceed at room temperature for 15-20 min, the absorbance at 535 nm was measured. The difference of values obtained between incubations at 37 and 4 °C was taken to represent the cell surface ferrireductase activity (A535/mg of protein).

Western Blot Analysis-- HeLa cells from a confluent 10-cm plate were collected in PBS containing 1 mM EDTA and washed three times in ice-cold PBS. Cells were resuspended in 100 µl of 25 mM HEPES, pH 7.4, 85 mM sucrose, 100 mM KCl, and 20 µM EGTA, frozen in liquid nitrogen, and thawed slowly at room temperature to disrupt cells. Nuclei and cell debris were removed by centrifugation at 850 × g for 10 min. The postnuclear supernatant was then collected and subjected to ultracentrifugation using a Sorval RP100AT3 rotor at 95,000 rpm for 15 min at 4 °C to collect the membrane fractions for SDS-PAGE. After electrophoretic transfer to nitrocellulose, Western blots were incubated for 1 h in a blocking solution containing 10 mM Tris, pH 8.0, 150 mM NaCl, 0.05% Tween 20, and 5% dried milk. Antiserum recognizing the predicted fourth extramembranous loop of SFT (Glu149-Met224) was raised by injection of a glutathione S-transferase fusion peptide into rabbits. After removal of glutathione S-transferase antibodies using glutathione-conjugated Sepharose-4B saturated with glutathione S-transferase, this antiserum was added in a 1:200 dilution in 10 mM Tris-Cl, pH 8.0, 150 mM NaCl, 0.05% Tween 20, and 5% dried milk. Following overnight incubation at 4 °C, the blot was washed three times with 10 mM Tris-Cl, pH 8.0, 150 mM NaCl, 0.05% Tween 20 and then incubated for 1 h at room temperature with alkaline phosphatase-linked goat anti-rabbit IgG (1:10,000 dilution). The blot was then copiously washed with 10 mM Tris, pH 8.0, 150 mM NaCl and incubated with nitro blue tetrazolium and 5-bromo-4-chloro-3-indoyl phosphate for color development. The alkaline phosphatase reaction was quenched by placing the blot in PBS containing 2 mM EDTA.

    RESULTS
Top
Abstract
Introduction
Procedures
Results
Discussion
References

SFT Stimulates Tf-independent Iron Uptake-- SFT, a "stimulator of Fe transport," was recently cloned by functional expression using Xenopus oocytes (23). Although it has been previously shown that SFT can stimulate Tf-mediated Fe transport by mammalian cells, the fact that SFT was identified by expression of Tf-independent transport activity indicates its involvement in non-Tf-bound Fe uptake across the plasma membrane. To characterize further the latter activity, iron uptake by HeLa cells stably expressing an SFT-GFP chimera, HeLa(SFT), was measured. The results of Fig. 1 show the time course of non-Tf-bound Fe uptake measured for both non-transfected HeLa cells (squares) and HeLa(SFT) (circles). 55Fe uptake by HeLa(SFT) cells is approximately 50% greater than the activity of control cells, demonstrating the stimulation of Tf-independent transport by SFT. As previously reported (26, 30), the transport of 55Fe is time- and temperature-dependent. At 37 °C, uptake is saturable, whereas at 4 °C, cell-associated radioactivity is less than 5% of the total cell-associated radioactivity measured at 37 °C.


View larger version (13K):
[in this window]
[in a new window]
 
Fig. 1.   Time course of iron uptake. HeLa(SFT) (circles) and control HeLa cells (squares) were incubated at 37 °C (filled symbols) or 4 °C (open symbols) in the presence of 1 µM 55FeNTA. At the indicated times, 55Fe uptake was quenched by rapidly chilling the cells on ice, followed by three washes with ice-cold PBS. Nonspecific surface-bound 55Fe was displaced by a brief (20 min) incubation on ice with 1 mM FeNTA in 25 mM HEPES, 150 mM NaCl, pH 7.4. Cells were then lifted off plates with 600 µl of PBS containing 1 mM EDTA. Cell-associated radioactivity was determined in duplicate 200-µl aliquots. The mean value (±S.E.) of 55Fe (fmol/µg of protein) taken up by HeLa cells is shown as a function of time. Results from an individual experiment are provided and reflect similar data obtained on three separate occasions.

To better define properties of SFT-mediated Fe transport, a series of inhibition experiments were carried out (Table I). FeNH4 citrate blocks uptake, indicating that the observed transport activity is specific for Fe rather than its chelating ligand (NTA). Excess diethylenetriaminepentaacetic acid (1 mM), a membrane-impermeant Fe3+-specific chelator, also completely blocks 55Fe uptake by both HeLa(SFT) and control cells. Interestingly, an Fe2+-specific chelator, ferrozine, also suppresses 55Fe accumulation by 60-70%, suggesting that SFT-mediated transport may not be specific for Fe3+. Treatment of cells with 50 µM chloroquine, a diffusable weak base that inhibits the dissociation of Fe from internalized Tf to block iron assimilation (31, 32), has no effect on SFT-mediated uptake of non-Tf bound Fe. This result suggests that SFT either functions at the plasma membrane or within endosomal compartments in a pH-independent manner, although the time course of uptake (Fig. 1) and the observed saturability of transport strongly argue for the involvement of a cell surface carrier in this process. Finally, it has been previously reported that Cd2+ inhibits Tf-independent Fe transport by HeLa (30) and K562 cells (26); the presence of 1 mM Cd2+ appears to partially antagonize SFT-mediated iron transport in a similar fashion.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Properties of Fe transport by SFT
Assimilation of non-Tf-bound iron was measured for cells incubated with 1 µM 55FeNTA for 30 min. Specific uptake was taken as the difference in cell-associated radioactivity determined at 37 and 4 °C. Transport activity in the presence of the indicated inhibitors was calculated as percent of uptake determined for untreated cells. To study the effects of cadmium, the cells were preincubated with 1 mM CdSO4 for 30 min prior to addition of 55FeNTA. Shown is the average of data obtained in three independent experiments.

To characterize further the kinetic properties of non-Tf-bound Fe uptake by HeLa(SFT) cells, initial rates of transport were measured as a function of FeNTA concentration. The results of these experiments (Fig. 2, panel A) reveal the typical Michaelis-Menten curve, indicating that the transport process is mediated by a limited number of carriers. A double-reciprocal plot of initial transport rates, v0, is shown in panel B (Fig. 2). HeLa(SFT) (circles) and control cells (squares) have nearly identical values for the apparent Km of uptake: 5.1 ± 1.0 versus 5.6 ± 1.1 µM (n = 4). These values are consistent with previous studies of Tf-independent Fe uptake by HeLa cells (30). As discussed by Sturrock et al. (30), this kinetic parameter is an "apparent Km" since it essentially reflects the property of iron accumulation by cells and not necessarily transport. Nevertheless, expression of SFT increases the Vmax of transport from 7.0 ± 1.2 to 14.7 ± 4.2 pmol/min/mg protein for HeLa(SFT); this increase would be expected if more transport sites were expressed in the stably transfected cells.


View larger version (12K):
[in this window]
[in a new window]
 
Fig. 2.   Kinetic analysis of iron uptake mediated by SFT. HeLa(SFT) (circles) and control HeLa cells (squares) were incubated with different concentrations of 55FeNTA for 15 min. Iron uptake measurements were carried out as detailed for Fig. 1 and Table I. Panel A, presents the Michaelis-Menten plot of HeLa(SFT) data obtained from four different experiments (±S.D.); v0 (pmol 55Fe/min/mg protein) is shown as a function of [Fe] (µM). Panel B, shows the double-reciprocal plot of data obtained for HeLa(SFT) cells (open circles) and HeLa cells (open squares) from a single experiment (±S.E.). Similar results were obtained on three separate occasions.

Western blot experiments reveal that the stably transfected cells do indeed express ~2-fold greater amounts of SFT/SFT-GFP. To raise antibodies against SFT, a glutathione S-transferase fusion peptide was prepared containing residues Glu149 to Met224, representing the integral membrane protein's "loop 4" or L4 domain. This segment is predominantly hydrophilic and therefore predicted to be extramembranous (23). Fig. 3 demonstrates that the antiserum raised against the L4 peptide recognizes both SFT and SFT-GFP. Endogenous HeLa cell SFT migrates as an 85-87-kDa species; this is the predicted mass of SFT homodimers that have been previously shown to remain associated on SDS-polyacrylamide gels even under reducing conditions (23). Interestingly, SFT-GFP also appears to form dimers that migrate as a 145-kDa species, consistent with the calculated mass for a homodimer of the chimera, but it is curious that mixed "dimers" are not observed. A plausible interpretation of this result is that heterodimers may be intrinsically unstable and therefore degraded by the HeLa cells.


View larger version (32K):
[in this window]
[in a new window]
 
Fig. 3.   Western blot analysis of SFT present in HeLa and HeLa(SFT) cells. Antiserum against the L4 domain of SFT was raised as detailed under "Experimental Procedures." Membrane fractions (100 µg of protein) from HeLa(SFT) and nontransfected control cells were electrophoresed on a 6% SDS-polyacrylamide gel and transferred to nitrocellulose. After blocking, the Western blot was incubated with a 1:200 dilution of primary antibody overnight and then washed and incubated with secondary alkaline phosphate-conjugated anti-rabbit antibody (1:10,000) prior to color development. SFT and SFT-GFP are denoted by right arrows; standards (rabbit muscle phosphorylase b, 97 kDa, and bovine serum albumin, 68 kDa) are denoted by left arrows.

Expression of SFT Does Not Stimulate HeLa Cell Ferrireduction-- Combined, the results discussed above indicate a strong correlation between the level of SFT expressed by HeLa cells and the Vmax of iron uptake, implicating a direct role for SFT as an Fe carrier. This idea is consistent with the characterized properties of SFT-mediated Fe uptake (Table I) that closely resemble features previously described for Tf-independent uptake (26). One cannot completely rule out the possibility, however, that SFT enhances Fe uptake through some rather indirect but stoichiometric interaction. A candidate role for SFT might be that of a ferrireductase to reduce Fe3+ to Fe2+ prior to translocation across the bilayer. Indeed, multiple studies have revealed the requisite function of such a reductase activity in the uptake of both Tf-bound (3, 4) and non-Tf-bound iron (5-8).

To investigate whether expression of SFT alters the intrinsic cell surface ferrireductase activity of HeLa cells (6), cell-mediated production of ferrocyanide from ferricyanide was measured (Fig. 4). Neither the rate nor the extent of ferrireduction is affected comparing the activity of HeLa(SFT) cells (circles) with the endogenous function of nontransfected cells (squares). This evidence excludes a functional role for SFT in stimulating cell surface ferrireductase activity. Our previous studies have shown that ferricyanide (the substrate used in the ferrireductase assay) is a competitive inhibitor of non-Tf-bound Fe3+ transport (5). Thus, these data suggest that SFT stimulates uptake by acting directly as or on the carrier component of this transport system rather than its associated ferrireductase activity and, moreover, that the action of the ferrireductase endogenous to HeLa cells is not rate-limiting for Tf-independent uptake.


View larger version (10K):
[in this window]
[in a new window]
 
Fig. 4.   SFT expression does not alter intrinsic activity of HeLa cell surface ferrireductase. Ferrireductase activity was measured as described under "Experimental Procedures." Briefly, cells were incubated with 10 µM K3Fe(CN)3 at 37 or 4 °C in Hanks' buffer. At times shown, 700 µl from the cell assay medium was mixed with 100 µl of 3 M sodium acetate, pH 6.4, 100 µl of 0.2 M citric acid, 50 µl of bathophenanthroline sulfonate, and 50 µl of 3.3 mM FeCl3 prepared in 0.1 M acetic acid to assay for ferrocyanide production. Results shown are the difference in absorption at 535 nm measured at 37 and 4 °C for duplicate samples (±S.E.). The time course of ferrireduction catalyzed by HeLa(SFT) (circles) and control cells (squares) is presented with similar results obtained in three separate experiments.

Cu Depletion Inhibits Tf- and Non-Tf-bound Fe Uptake Mediated by SFT-- Numerous studies have established a connection between copper and iron metabolism (2, 15, 33). For example, yeast cells defective in Cu transport display diminished Fe uptake activity (34). In studies of cultured human cells, Tf-mediated Fe uptake was also found to be reduced by experimentally induced Cu depletion (24). To investigate whether Cu plays a role in SFT function, fetal bovine serum was depleted by dialysis against the chelator TRIEN. After 4 days in culture with Cu-depleted serum, HeLa cell SOD activity was decreased by 60-70%, consistent with previous results reported by Percival (28). Cells grown under this condition have markedly reduced levels of Tf-dependent and -independent Fe uptake activity (Fig. 5). Notably, although HeLa(SFT) cells have 51 ± 17% greater Tf-mediated uptake activity (panel A) and 38 ± 11% greater non-Tf Fe transport (panel B), Cu depletion reduces both activities to the same level as non-transfected control HeLa cells. Thus, SFT apparently cannot functionally stimulate Fe uptake in Cu-depleted cells. The decrease in Fe assimilation by both pathways is marked as follows: Tf-mediated uptake is diminished by 70-80%, whereas Tf-independent Fe transport drops by ~50%. The fact that the effects of Cu depletion on HeLa cell Tf-mediated uptake are more pronounced may indicate subtle differences between Tf-dependent and -independent Fe transport mechanisms. Studies in yeast have implicated the existence of multiple iron uptake systems in high eukaryotes (2, 9-12). It is possible that certain Fe transport mechanism(s) in mammalian cells, other than SFT-mediated uptake, maintain normal function despite the Cu deficiency. For example, the human equivalent of the rodent divalent cation transporter DCT1/nRAMP2 may participate in HeLa cell Tf-independent Fe uptake, and its activity may not be affected in the Cu-depleted state.


View larger version (11K):
[in this window]
[in a new window]
 
Fig. 5.   Effects of Cu depletion on iron uptake. To lower cellular Cu levels, serum was dialyzed against 30 mM TRIEN in PBS and added to culture media supplemented with or without 2 µM CuCl2. After 4 days of culture in the Cu-depleted media, cells displayed Cu,Zn-SOD levels that were 60-70% reduced (not shown). Both HeLa(SFT) and control HeLa cells were cultured in the Cu-depleted (solid bars) or Cu-replete medium (open bars). Tf-mediated Fe uptake (panel A) and Tf-independent Fe uptake (panel B) activities were measured as described under "Experimental Procedures." 55Fe uptake was calculated as percent control measured for cells cultured under Cu replete conditions. Shown are the mean values (±S.D.) from three independent experiments.

Cu Depletion Reduces HeLa Cell Surface Ferrireductase Activity-- Because ferrireduction has been implicated in the membrane translocation of Fe released from Tf within endosomes (3, 4) as well as the import of non-Tf-bound Fe at the cell surface (5-8), one explanation for the effects of Cu depletion is that ferrireductase activity may be impaired, thus inhibiting Fe assimilation from both pathways. To examine the influence of Cu depletion on ferrireduction, cell-mediated reduction of ferri- to ferrocyanide was monitored as described above. The ferrireductase activities for HeLa and HeLa(SFT) cells cultured in either Cu-depleted medium (solid bars) or Cu-repleted medium (open bars) are presented in Fig. 6. Expression of SFT does not significantly affect total cell surface ferrireductase activity consistent with the data shown in Fig. 4. However, depletion of cellular Cu levels diminishes the cell surface reductase activity by ~60%; for comparison, under these same conditions uptake of non-Tf-bound Fe falls by ~50% (Fig. 5B). Hence, in the Cu-depleted state, cell surface ferrireductase activity appears to become rate-limiting for transport. A reasonable conclusion drawn from these results is that the influence of Cu on SFT function in non-Tf Fe uptake may be due to decreased cell surface ferrireductase activity.


View larger version (13K):
[in this window]
[in a new window]
 
Fig. 6.   Cu depletion reduces HeLa cell surface ferrireductase activity. Ferrireductase activity was measured as described for Fig. 4. Both HeLa and HeLa(SFT) cells were cultured under Cu-replete (open bars) or Cu-depleted conditions (solid bars) for 4 days prior to the measurements of ferrireductase activities. SOD activity was inhibited by 62% for HeLa(SFT) and by 67% for HeLa cells on this occasion. Shown are the average of duplicate samples (±S.E.), and the data are typical of results obtained on three separate occasions.

SFT Stimulates Fe2+ Uptake and This Activity Is Unaffected by Cu Depletion-- According to the envisioned mechanism of iron transport, the ferrireductase acting to convert Fe3+ to Fe2+ would act upstream of an Fe2+ carrier that translocates the cation across the membrane bilayer. If the influence of Cu on Fe uptake can be attributed to the diminished ferrireductase activity observed for depleted cells as discussed above (Fig. 6), a prediction would be that the transport of Fe2+ remains unaffected by these conditions. Related to this hypothesis is the idea that SFT function, which is impaired by Cu depletion (Fig. 5) and which does not modulate ferrireductase activity (Fig. 4), may stimulate Fe uptake by acting as or on the putative Fe2+ carrier mechanism.

To test whether SFT mediates Fe2+ uptake, transport assays were performed with 55FeCl3 prepared in buffer containing freshly dissolved ascorbate (1:20 molar ratio) to effectively reduce the radioactive iron. The time course of uptake presented in Fig. 7 (panel A) demonstrates that HeLa(SFT) cells (circles) have enhanced transport activity relative to nontransfected cells (squares). HeLa(SFT) cells display levels of uptake 50% greater than control cells, similar to the results described earlier (Fig. 1). Although these data do not necessarily discriminate that Fe2+ is the actual cationic form translocated across the bilayer, our combined results do demonstrate that SFT functionally stimulates Fe assimilation regardless of whether cells are presented with ferric or ferrous forms. This activity is distinct from that characterized for the rat intestinal iron transporter DCT1, which appears to recognize and mediate uptake of divalent cations alone (20).


View larger version (13K):
[in this window]
[in a new window]
 
Fig. 7.   SFT stimulates Fe2+ uptake. Panel A presents the time course of Fe2+ uptake by HeLa(SFT) (circles) and control cells (squares) incubated at 37 °C (filled symbols) or 4 °C (open symbols) with 1 µM 55FeCl3 in the presence of freshly dissolved ascorbate at a 1:20 molar ratio. At the indicated times, cells were placed on ice and washed several times with ice-cold PBS to remove nonspecifically bound radioactivity, and cell-associated cpm were measured as described in Fig. 1. Panel B compares the accumulation of 55Fe for HeLa(SFT) and control cells cultured in either Cu-depleted (solid bars) or Cu replete (open bars) medium for 4 days. Fe2+ uptake assays were carried out as for panel A with a 2-h incubation. Shown are the mean values (±S.D.) obtained from three different experiments.

Since our results indicate that cell surface ferrireductase activity is the potential Fe3+ transport factor affected by Cu depletion, Fe2+ uptake assays were also performed with Cu-depleted HeLa(SFT) and control cells. Panel B (Fig. 7) further demonstrates the stimulation of Fe uptake by SFT (compare open bars). Importantly, nearly identical levels of transport are maintained for both HeLa(SFT) and control cells that have been Cu-depleted (compare open bars with solid bars). Thus, the ability of HeLa cells to take up iron presented in the ferrous form is insensitive to Cu depletion; moreover, stimulation of this transport activity by SFT is also unaffected. These results indicate that a HeLa cell ferrireductase activity that is impaired by depletion of cellular Cu levels must function upstream of SFT to enable its apparent stimulation of Fe3+ uptake and that this activity, which presumably mediates the reduction of Fe3+ to Fe2+, is not required for the apparent stimulation of Fe2+ uptake by SFT.

    DISCUSSION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

The stimulation of non-Tf-bound Fe transport by SFT has all of the features previously described for Tf-independent transport by K562 (26) and HeLa (30) cells. Uptake is time- and temperature-dependent, inhibited by Cd2+, blocked by Fe3+ and Fe2+ chelators, and appears specific for the cation rather than its anionic ligand. Moreover, SFT function in Tf-independent transport also appears to depend on cell surface ferrireductase activity, as previously characterized for uptake of ferric iron (5-8). The observations that HeLa(SFT) cells display a Vmax two times greater than non-transfected HeLa cells and that levels of SFT expression are approximately doubled in the stably transfected cell line directly support the hypothesis that SFT itself is a membrane carrier for iron. Indeed, SFT is an integral membrane protein localized to the plasma membrane and endosomal domains (23); its expression stimulates both Tf-dependent and -independent Fe assimilation (see Fig. 5), and it contains an REXXE domain putatively involved in Fe binding (10). Mutation of these critical glutamic acid residues results in the loss of function of SFT (23), further implicating a direct role for SFT in the translocation of Fe across membrane bilayers. Despite the strength of this combined evidence, however, it is important to keep in mind the consideration that the enhanced non-Tf-bound Fe uptake by HeLa(SFT) cells could be a secondary consequence of SFT expression. Recent controversies surrounding the precise role for cystic fibrosis transmembrane conductance regulator in ATP transport reflect similar concerns (35). Until rigorous evidence is obtained through reconstitution studies, the precise role of SFT in the transmembrane transport of Fe may remain elusive (see below).

The complexities associated with membrane transport of Fe have been revealed by genetic studies in yeast. Multiple carrier mechanisms have been defined (9-12), similar to recent reports investigating iron uptake in mammalian systems (20, 22, 23). FET4, for example, appears to play a direct role in the uptake of Fe2+ (12); this activity resembles the function of the rodent DCT1/nRAMP2 transporter in intestinal iron uptake (20, 22). It is likely that the latter transporter may play a role in endosomal transport of Fe as well since it has been discovered that the Belgrade rat, which has genetic defects in the release of Tf-bound Fe from endosomes (36), harbors the exact same mutation in DCT1/nRAMP2 as the mk mouse (37). One notable difference is the ability of DCT1/nRAMP2 to mediate uptake of other divalent cations (20). The idea that a common carrier exists to translocate iron and other metals across the plasma membrane is consistent with observations made for uptake by reticulocytes (38), HeLa cells (30), fibroblasts (30, 39), and hepatocytes (8, 40) but contrasts with our studies of K562 cells that suggest this erythroleukemia cell line has distinct transport properties (26). The specificity for Fe by FET4 not only resembles the characteristics of a second yeast iron transport mechanism involving FET3 and FTR1 but also parallels the properties we have defined for SFT, which was identified by screening a K562 cell cDNA library (23). Both FET4 and FET3/FTR1 depend on the function of FRE1, a yeast ferrireductase, to transport Fe3+ (13, 14). Similarly, our investigation demonstrates a strong dependence on HeLa cell surface ferrireductase activity for SFT's stimulation of non-Tf-bound Fe3+ uptake. This correlation is revealed by the finding that Cu depletion impairs ferrireductase function and that expression of SFT is unable to compensate for the loss in Fe3+ uptake under these conditions (Fig. 5).

Certain facets of the yeast FTR1/FET3 iron uptake system are comparable to elements associated with SFT function. FTR1 and SFT are both integral membrane proteins containing six transmembrane-spanning domains and are of similar size (~40 kDa). Both of these putative carriers have REXXE motifs that Stearman et al. (10) speculate may be involved in iron binding. In contrast, FET4 lacks the appearance of similar motifs within its primary sequence and has a greater mass of 63 kDa (11). The activities of both FTR1 and SFT in the transport of ferric iron also appear to depend on Cu. However, our investigation reveals clear mechanistic distinctions between yeast and man in the relationship of Cu in cellular iron uptake.

The importance of Cu in yeast Fe transport is believed to be associated with its activity as a cofactor for FET3. FET3 was identified early in the search for membrane carriers of iron (9); in a concurrent search for iron transport proteins, Dancis et al. (34) uncovered the necessity for a copper transport protein, CTR1. The connection between FET3 and CTR1 was revealed by the findings that FET3 was a multicopper oxidase (9) and that although Delta ctr1Delta fet3 yeast strains were unable to take up Fe2+, activity could be restored to Delta ctr1 yeast grown in high copper media (34). Later studies also defined the requirement for an intracellular Cu transporter, CCC2 (41). Finally, the role of FTR1 in FET3-mediated iron uptake was defined by Klausner and colleagues (10) when they characterized yeast transport mutants that phenotypically resembled fet3 mutants but had defects that could not be compensated for by addition of excess Cu to the growth medium. FTR1 appears to be required for FET3 expression and loading with copper (10); elimination of the FTR1 gene results in a block in FET3 biosynthesis and expression at the cell surface, whereas FET3 deletion mutants reciprocally cannot express FTR1 at the plasma membrane. The idea that FTR1 is an iron transporter is supported by the finding that mutants in its REXXE domain cannot take up iron despite the fact that FET3 oxidase activity is unimpaired (10).

The multifactorial nature of Fe3+ uptake by yeast, requiring FRE1, FET4, or FTR1/FET3, as well as the Cu-transporting proteins CTR1 and CCC2, emphasizes the concerns raised earlier regarding the exact role of SFT in mammalian non-Tf-bound Fe transport. Individually, each of these yeast genes appears to modulate iron assimilation and could serve as stimulators of Fe transport. To this end, a complete description of yeast Fe import also remains elusive since iron is required for growth, and fet3fet4 deletion strains, predicted to be defective in both of the pathways described above, are still capable of survival (2, 12).

Similar to the mechanism of Fe uptake in yeast, Cu depletion of HeLa cells also results in defective Tf- and non-Tf-bound iron assimilation (Fig. 5), yet our studies demonstrate that at least for the latter activity, impaired cell surface ferrireductase function can account for this loss (Fig. 6). Although it is possible that a ferroxidase activity analogous to FET3 could be compromised by Cu deficiency, under our assay conditions both basal and SFT-stimulated Fe2+ uptake remains unperturbed. Because oxidation of Fe2+ by FET3 is apparently required for FTR1 function in yeast (10), we conclude that if a similar activity is involved in SFT-mediated iron uptake, it is unlikely to be dependent on cellular Cu status.

This investigation yields two related findings regarding the function of SFTs: 1) SFT stimulates the import of iron presented as either Fe2+ or Fe3+, and 2) it is unlikely that SFT simply acts as a ferrireductase to stimulate Fe uptake. Because our results clearly demonstrate that Cu depletion inhibits ferric iron uptake and that ferrireduction is impaired under these conditions, we conclude that SFT-mediated Fe transport is downstream of the cell surface ferrireductase activity, but whether its activity stimulates the membrane translocation of ferrous iron alone is uncertain. As discussed above, FRE1/2 ferrireductase activity is required for yeast iron uptake when presented in the ferric form (13, 14), yet the activity of the FET3 oxidase is also necessary for the role of FTR1s in transport; these observations prompted Stearman et al. (10) to suggest that FTR1 may bind both Fe2+ and Fe3+ during its mechanism of transmembrane transport. Importantly, the yeast reductase FRE1 has been identified to be a b-type cytochrome similar to the NADPH oxidase gp91phox. Shatwell et al. (42) have reported biophysical characteristics of FRE1 indicating that it is a heme protein; this is consistent with early investigations of Lesuisse and Labbe (43) in which they describe the lack of ferrireductase activity in heme-deficient yeast strains. In this context, analogies in the role of copper for ferric iron uptake between yeast and man possibly may be drawn since Cu deficiency is known to impair heme biosynthesis (see Ref. 33 and references therein). Therefore, one may speculate that the influence of Cu depletion on HeLa cell Fe uptake may result from defective heme synthesis leading to the loss of a cytochrome b-like cell surface ferrireductase. Further experimentation is required to fully elucidate the role of Cu in mammalian iron assimilation and its exact function in SFT-mediated transport.

    FOOTNOTES

* This work was supported by National Institutes of Health Grant DK52371.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger Established Investigator of the American Heart Association. To whom correspondence should be addressed: Dept. of Nutrition, Harvard School of Public Health, 666 Huntington Ave., Boston, MA 02115. Tel.: 617-432-3267; Fax: 617-432-2435.

1 The abbreviations used are: Tf, transferrin; SFT, stimulator of Fe transport; GFP, green fluorescent protein; DMEM, Dulbecco's modified Eagle's medium; PBS, phosphate-buffered saline; NTA, nitriloacetic acid; SOD, superoxide dismutase; Fe, iron; Cu, copper; TRIEN, TriethylenetetramineTM.

    REFERENCES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

  1. Gutierrez, J. A., and Wessling-Resnick, M. (1996) Crit. Rev. Eukaryotic Gene Expr. 6, 1-14[Medline] [Order article via Infotrieve]
  2. DeSilva, D. M., Askwith, C. C., and Kaplan, J. (1996) Physiol. Rev. 76, 31-47[Abstract/Free Full Text]
  3. Nunez, M. T., Gaete, V., Watkins, J. A., Glass, J. (1990) J. Biol. Chem. 265, 6688-6692[Abstract/Free Full Text]
  4. Watkins, J. A., Altazan, J. D., Elder, P., Li, C. Y., Nunez, M. T., Cui, X. X., Glass, J. (1992) Biochemistry 31, 5820-5830[Medline] [Order article via Infotrieve]
  5. Inman, R. S., Coughlan, M. M., and Wessling-Resnick, M. (1994) Biochemistry 33, 11850-11857[Medline] [Order article via Infotrieve]
  6. Jordan, I., and Kaplan, J. (1994) Biochem. J. 302, 875-879[Medline] [Order article via Infotrieve]
  7. Riedel, H. D., Remus, A. J., Fitscher, B. A., Stremmel, W. (1995) Biochem. J. 309, 745-748[Medline] [Order article via Infotrieve]
  8. Randell, E. W., Parkes, J. G., Olivieri, N. F., Templeton, D. M. (1994) J. Biol. Chem. 269, 16046-16053[Abstract/Free Full Text]
  9. Askwith, C., Eide, D., Van Ho, A., Bernard, P. S., Li, L., Davis-Kaplan, S., Sipe, D. M., Kaplan, J. (1994) Cell 76, 403-410[Medline] [Order article via Infotrieve]
  10. Stearman, R., Yuan, D. S., Yamaguchi-Iwai, Y., Klausner, R. D., Dancis, A. (1996) Science 271, 1552-1557[Abstract]
  11. Dix, D. R., Bridgham, J. T., Broderius, M. A., Byersdorfer, C. A., Eide, D. J. (1994) J. Biol. Chem. 269, 26092-26099[Abstract/Free Full Text]
  12. Dix, D., Bridgham, J., Broderius, M., and Eide, D. (1997) J. Biol. Chem. 272, 11770-11777[Abstract/Free Full Text]
  13. Dancis, A., Klausner, R. D., Hinnebusch, A. G., Barriocanal, J. G. (1990) Mol. Cell. Biol. 10, 2294-2301[Medline] [Order article via Infotrieve]
  14. Georgatsou, E., and Alexandraki, D. (1994) Mol. Cell. Biol. 14, 3065-3073[Abstract]
  15. Winzerling, J. J., and Law, J. H. (1997) Annu. Rev. Nutr. 17, 501-526[CrossRef][Medline] [Order article via Infotrieve]
  16. Lee, G. R., Nacht, S., Lukens, J. N., Cartwright, G. E. (1968) J. Clin. Invest. 47, 2058-2069[Medline] [Order article via Infotrieve]
  17. Owen, C. A. (1973) Am. J. Physiol. 224, 514-518[Medline] [Order article via Infotrieve]
  18. Van Den Berg, G. J., Van Houwelingen, F., Lemmens, A. G., Beynen, A. C. (1992) Biol. Trace Elem. Res. 35, 77-79[Medline] [Order article via Infotrieve]
  19. Harris, Z. L., Takahashi, Y., Miyajima, H., Serizawa, M., MacGillivray, R. T. A., Gitlin, J. A. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 2539-2543[Abstract]
  20. Gunshin, H., Mackenzie, B., Berger, U. V., Gunshin, Y., Romero, M. F., Boron, W. F., Nussberger, S., Gollan, J. L., Hediger, M. A. (1997) Nature 338, 482-487[CrossRef]
  21. Edwards, J. A., and Hoke, J. E. (1972) Proc. Soc. Exp. Biol. Med. 141, 81-84
  22. Fleming, M. D., Trenor, C. C., Su, M. A., Foernzler, D., Beier, D. R., Dietrich, W. F., Andrews, N. C. (1997) Nat. Genet. 16, 383-386[Medline] [Order article via Infotrieve]
  23. Gutierrez, J. A., Yu, J., Rivera, S., and Wessling-Resnick, M. (1997) J. Cell Biol. 139, 895-905[Abstract/Free Full Text]
  24. Tong, K. K., Hannigan, B. M., and McKerr, G. (1996) Br. J. Nutr. 75, 97-108[Medline] [Order article via Infotrieve]
  25. Teichmann, R., and Stremmel, W. (1990) J. Clin. Invest. 86, 2145-2153[Medline] [Order article via Infotrieve]
  26. Inman, R. S., and Wessling-Resnick, M. (1993) J. Biol. Chem. 268, 8521-8528[Abstract/Free Full Text]
  27. Bradford, M. M. (1976) Anal. Biochem. 72, 248-254[CrossRef][Medline] [Order article via Infotrieve]
  28. Percival, S. S. (1992) Proc. Soc. Exp. Biol. Med. 200, 522-527[Abstract]
  29. Schweinzer, E., and Goldenberg, H. (1992) Eur. J. Biochem. 206, 807-812[Abstract]
  30. Sturrock, A., Alexander, J., Lamb, J., Craven, C. M., Kaplan, J. (1990) J. Biol. Chem. 265, 3139-3145[Abstract/Free Full Text]
  31. Ciechanover, A., Schwartz, A. L., Dautry-Varsat, A., and Lodish, H. F. (1983) J. Biol. Chem. 258, 9681-9689[Abstract/Free Full Text]
  32. Morgan, E. H. (1981) Biochim. Biophys. Acta 62, 119-134
  33. Chan, W. Y., and Rennert, O. M. (1980) Ann. Clin. Lab. Sci. 10, 338-344[Abstract]
  34. Dancis, A., Yuan, D. S., Haile, D., Askwith, C., Eide, D., Moehle, C., Kaplan, J., and Klausner, R. D. (1994) Cell 76, 393-402[Medline] [Order article via Infotrieve]
  35. Devidas, S., and Guggino, W. B. (1997) Curr. Opin. Cell Biol. 9, 547-552[CrossRef][Medline] [Order article via Infotrieve]
  36. Garrick, M. D., Gniecko, K., Liu, Y., Cohan, D. S., Garrick, L. M. (1993) J. Biol. Chem. 268, 14867-14874[Abstract/Free Full Text]
  37. Fleming, M. D., Romano, M. A., Su, M. A., Garrick, L. M., Garrick, M. D., Andrews, N. C. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 1148-1153[Abstract/Free Full Text]
  38. Morgan, E. H. (1988) Biochim. Biophys. Acta 943, 428-439[Medline] [Order article via Infotrieve]
  39. Kaplan, J., Jordan, I., and Sturrock, A. (1991) J. Biol. Chem. 266, 2997-3004[Abstract/Free Full Text]
  40. Barisani, D., Berg, C. L., Wessling-Resnick, M., and Gollan, J. L. (1995) Am. J. Physiol. 269, G570-G576[Abstract/Free Full Text]
  41. Yuan, D. S., Stearman, R., Dancis, A., Dunn, T., Beeler, T., and Klausner, R. D. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 2632-2636[Abstract]
  42. Shatwell, K. P., Dancis, A., Cross, A. R., Klausner, R. D., Segal, A. W. (1996) J. Biol. Chem. 271, 14240-14244[Abstract/Free Full Text]
  43. Lesuisse, E., and Labbe, P. (1989) J. Gen. Microbiol. 135, 257-263[Medline] [Order article via Infotrieve]


Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.